This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

DAVID M. PERRY, M.D.; WILLIAM M. M. KIRBY, M.D.

AMA Arch Intern Med. 1960;105(6):929-934.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Amphotericin B* has been shown to have marked fungistatic action in vitro against a number of nonpathogenic and pathogenic fungi, including Candida albicans, Cryptococcus neoformans, Histoplasma capsulatum, Blastomyces dermatiditis, and Coccidioides immitis.^1-3 Some fungi, such as nocardia and aspergillus, are relatively more resistant to the antibiotic. In vivo, amphotericin has been protective in experimental animals infected with C. albicans, C. neoformans, H. capsulatum, and C. immitis.^2,4-6 In patients with disseminated fungus diseases, amphotericin has been effective in the therapy of histoplasmosis and blastomycosis,^7,8 and patients with cryptococcal meningitis have usually responded to treatment.^8-11 However, the number of patients with the disseminated form of coccidioidomycosis so far treated with amphotericin is relatively small, and the results of therapy have been inconclusive. Aside from difficulties in evaluation due to the variable course of the disease, an apparent lack of response may have been due in some instances to inadequate dosage of amphotericin. . . . [Full Text PDF of this Article]

Author Affiliations
Seattle, Wash.

From the Department of Medicine, University of Washington School of Medicine and The King County Hospital, Seattle.

Footnotes
Submitted for publication Aug. 10, 1959.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?